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Summary
Objectives: The Swiss Cohort Study on Air Pollution and Lung
Diseases in Adults (SAPALDIA) was designed to investigate the
health effects from long-term exposure to air pollution.
Methods: The health assessment at recruitment (1991) and at
the first reassessment (2001–3) consisted of an interview about
respiratory health, occupational and other exposures, spirome-
try, a methacholine bronchial challenge test, end-expiratory car-
bon monoxide (CO) measurement and measurement for atopy.
A bio bank for DNA and blood markers was established. Heart
rate variability was measured using a 24-hour ECG (Holter) in a
random sample of participants aged 50 years and older. Con-
centrations of nitrogen dioxide (NO2), sulphur dioxide (SO2),
ozone (O3) and particulates in ambient air have been monitored
in all study areas since 1991. Residential histories collected over
the 11 year follow-up period coupled with GIS modelling will
provide individual long-term air pollutant exposure estimates.
Results: Of 9651 participants examined in 1991, 8715 could be
traced for the cohort study and 283 died. Basic information
about health status was obtained for 8047 individuals (86% of
alive persons), 6528 individuals (70%) agreed to the health ex-
amination and 5973 subjects (62%) completed the entire pro-
tocol. Non-participants in the reassessment were on average
younger than participants and more likely to have been smok-
ers and to have reported respiratory symptoms in the first as-
sessment. Average weight had increased by 5.5 kg in 11 years
and 28% of smokers in 1991 had quit by the time of the re-
assessment.
Keywords: Cohort study – Longitudinal study – Adults – 
Chronic disease – Air pollution.
The most powerful approach for studying long-term effects
from ambient air pollution on health is the long-term
prospective follow-up of well-defined population-based co-
horts with well-characterized air pollution exposure infor-
mation (European Science Foundation 1998). There are 
currently only five cohort studies in adults, with published
results, that address the long-term impact of air pollution
(Abbey et al. 1999; Dockery et al. 1993; Finkelstein et al.
2004; Hoek et al. 2002; Pope et al. 2002; 1995). All studies
but one are based in the US and three of them (Dockery et
al. 1993; Hoek et al. 2002; Pope et al. 2002), have only pub-
lished findings related to mortality. The relation of long-
term exposure to air pollution with respiratory and cardio-
vascular health and morbidity has yet to be measured in a
large prospective cohort study in Europe. The large Euro-
pean Community Respiratory Health Survey (ECRHS) de-
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signed to measure natural history and risk factors for respi-
ratory diseases (particularly asthma and allergy) across 
Europe has recently included air pollution exposure assess-
ment in its protocol (Burney et al. 1994; Hazenkamp-von
Arx et al. 2004). However, the Swiss Cohort Study on Air
Pollution and Lung Diseases in Adults (SAPALDIA) is the
only prospective cohort study of respiratory and cardio-
vascular health in adults in Europe with detailed individual
residential exposure histories as a key element of the assess-
ment of effects from long-term exposure to air pollution.
The SAPALDIA cohort is a random population sample of 
9 561 adults recruited and examined in 1991 (for detailed 
description of methods see (Martin et al. 1997)). There were
extensive health examinations, a detailed assessment of 
personal risk factors, assessment of average exposure to the
pollutants O3, NO2, SO2 and PM10 in ambient air and assess-
ment of individual exposure to NO2. Findings from the study
showed effects from passive smoking exposure on respira-
tory symptoms (Leuenberger et al. 1994) and from air pol-
lutant on lung function and symptoms (Ackermann-Liebrich
et al. 1997; Künzli et al. 2000; Schindler et al. 1998; 2001;
Zemp et al. 1999) and from occupational exposure and 
atopy on bronchial responsiveness (Leuenberger et al. 2000;
Schwartz et al. 2002). References values from lung function
(Brändli et al. 1996; 2000) and the prevalence of atopy and 
allergic symptoms have been described (Strupler et al. 1997;
Wüthrich et al. 1995; 1996; 1999).
Monitoring of air pollutants, meteorology and pollen has
been conducted in all study areas since 1991. Regular 
mailings to the 9651 original participants has ensured that
changes in residential address and deaths (n = 283) amongst
participants since 1991 have been updated. Of the surviving
9368 participants, 93% (8715) could be traced between
2001–2003. This paper describes the health examinations,
the bio bank, the environmental monitoring, and the assess-
ment of air pollution exposure and basic characteristics of
the participants in SAPALDIA 2.
Methods
The milestones of the SAPALDIA study (1991–2001)
The eight study areas (Geneva, Basel, Lugano, Aarau, Wald,
Payerne, Davos, Montana) were chosen to represent the 
variety of environmental conditions in respect to geography,
climate, degree of urbanisation and air pollution in Switzer-
land. From the local registries of inhabitants of these areas
random population samples of persons aged 18–60 years,
who had been residents in the respective area for at least
three years, were then drawn (Martin et al. 1997).
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Health examinations were conducted at the eight local cen-
tres over the course of one year in 1991 and repeated in 2002.
Detailed description of the 1991 examinations can be found
elsewhere (Martin et al. 1997).
Contact with the 9 651 participants of SAPALDIA 1 (in-
cluding monitoring of mortality) has been facilitated by 
regular mailings and updates every 1.5 years through the 
information collected from participants by mail or from 
local registries of inhabitants. The residential history data-
base was checked at the local registries in all study areas in
1998 and 1999. 
Recruitment for the SAPALDIA follow-up (2001–2003)
Extensive efforts were made to contact all original partici-
pants of SAPALDIA 1 for the follow-up examination in
SAPALDIA 2. A letter of invitation describing the health
examinations, was sent to all former participants who could
be traced. The letter contained a screening questionnaire
(with 13 questions about respiratory symptoms, smoking,
date of birth and address) and a prepaid addressed envelope
for the return of the response to the local study centre. Up 
to three letters were sent and up to 12 telephone calls made
(at different times during the day including morning, noon,
evening and weekends) in an attempt to contact the non-
responders. In non-responding subjects without telephone
number, SAPALDIA personnel made home visits. If all 
attempts to make contact failed; the subject was considered
to be untraceable (n = 653, 6.8%). 
The protocols for SAPALDIA and the European Com-
munity Respiratory Health Survey (ECRHS) (Burney 
et al. 1994) are similar (Tab. 1) and participants from the
SAPALDIA Basle centre aged 18–44 in 1991 are also par-
ticipants in the ECRHS study. 
Since ECRHS II was initiated slightly in advance of 
SAPALDIA 2, examinations at the Basle centre preceded
those in other SAPALDIA centres. Examinations in Basle
were started in July 2001, and between October 2001 and
January 2002 in the other centres (Aarau, Davos, Geneva,
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Lugano, Montana, Payerne, Wald). Examinations in all cen-
tres were completed by the end of February 2003. 
Informed consent
Ethical approval for SAPALDIA 2 was given by the central
ethics committee of the Swiss Academy of Medical Sciences
and the Cantonal Ethics Committees for each of the eight
examination areas. The consent information provided to
participants described the health examination including 
the bronchial challenge, the ambulatory electrocardiogram
(ECG) and blood collection. Additionally there was infor-
mation about data protection and the genetic assessments.
Participants were required to give written consent before
any part of the health examination was conducted and were
provided with written consent information to read and were
given the opportunity to ask questions about the examina-
tion. Subjects could either give global consent (for all health
examinations) or agree to each investigation separately.
Documentation
All study documentation, including questionnaires and pro-
tocols, was provided in German, French and Italian because
native languages differed between SAPALDIA centres.
Documents were usually conceived in German or English
and then translated in French and Italian. Translations were
cross-checked in simultaneous readings with SAPALDIA
research personnel who were native speakers of the respec-
tive languages and fluent in at least one of the other lan-
guages. This procedure had already been used in 1991 and at
that time back-translations were also used for validation. As
the majority of questionnaires were already available in 
the three languages, back-translations were unnecessary in
SAPALDIA 2.
Interview administered main questionnaire
The interview was conducted by a trained fieldworker 
and answers from the participant were entered directly 
into an Access database on a personal computer. As in
SAPALDIA 1, the interview included questions about his-
tory of respiratory symptoms, allergic diseases, general
health, living and working environment, smoking habits, 
exposure to traffic, exposure to environmental tobacco
smoke and animals. In SAPALDIA 2 the questionnaire was
extended with additional questions about chronic diseases,
including heart disease, questions about dietary habits
(adapted from the Swiss Health Questionnaire (Bundesamt
für Statistik 2001/2004), physical activity (derived from the
ECRHS II- and the Swiss Health Questionnaire) and sleepi-
ness (derived from the Epworth Sleepiness Scale (Johns
1991)). Present and past medication use was recorded in 
detail; including type, dose, start date of medication use and
duration. 
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Table 1 Comparison of assessments in SAPALDIA and ECRHS
SAPALDIA SAPALDIA ECRHS 
Cross-sectional 1991 Follow-up 2001–2003 Follow-up 2001
Questionnaires
PC based interview yes yes yes
Paper questionnaires:
– SF36, quality of life no yes yes
– JuniperAsthma quality of life no yes yes
– Occupational exposure no yes yes
– Women’s questionnaire no yes yes (some centres)
Lung parameter assessment
Spirometry yes yes yes
Bronchochallenge yes yes yes
End-expiratory CO yes yes no
Cardiovascular assessments
Blood pressure no yes no
Ambulatory ECG no yes no
Assessment of allergy
Skin prick test yes no no
Blood markers (IgE) yes yes yes
Assessment of genetic factors
Blood for DNA isolation no yes yes
Assessment of genotypes no yes yes (some centers)
Assessment of other risk factors in blood
Cardiovascular risk factors no yes no
Hormones in females no yes yes (some centres)
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Additional questionnaires administered included the Qual-
ity of life (SF36) questionnaire (Ware 1994), the Juniper
Asthma quality of life questionnaire (Juniper et al. 1993)
(given to the subjects who had answered “yes” to the ques-
tion: “Have you ever had asthma?”) and a women’s ques-
tionnaire (with questions about menstruation, menopausal
status and intake of hormones) (Tab. 1 and 3a). In addition,
a card was handed to all pre-menopausal women with the re-
quest to send the card back with the date that their next
menstrual cycle commenced in order to determine their 
hormonal status at the time of health examination. A job 
exposure matrix (Kennedy et al. 2000) was used to assess 
occupational exposures since SAPALDIA 1. Participants
who had worked as cleaners (in a job and at home), nurses,
metal workers, solderers, welders and participants who had
worked with disinfectants were also asked to complete an
occupational questionnaire specific to the occupational acti-
vity or exposure. Participants also completed an address/
ZIP code table indicating residential location(s) for the 
period of 1991–2001.
The computer-based interview took on average 45 minutes
per participant. If participants were unable or unwilling to
come to the examination centre, one of two shorter ques-
tionnaires were administered over the telephone. The short
questionnaire contained a selection of 64 questions from 
the main interview about respiratory symptoms and medica-
tion, chronic diseases, current occupation, exposure to traf-
fic, active and passive smoking and emergency visits at the
hospital. The ultra-short questionnaire comprised 32 ques-
tions about respiratory symptoms, medication, current occu-
pation, exposure to traffic, active and passive smoking.
The following definitions based on answers in the main
questionnaire are used in Figures 1a and 1b:
Current smoker: Positive answer to the question “Have you
ever smoked for as long as a year?” (“yes” means at least 
20 packs of cigarettes or 360 grams of tobacco in a lifetime or
at least one cigarette per day or one cigar a week for one year).
Chronic cough: Positive answer to the question “Do you
usually cough during the day, or at night, on most days for as
much as three months each years?” and an answer of > 2 to
the question “For how many years have you coughed like
this?”
Chronic phlegm: Positive answer to the question “Do you
usually bring up phlegm from your chest during the day or at
night on most days for as much as three months each years?”
and an answer of > 2 to the question “For how many years
have you brought up phlegm like this?”
Wheeze: Positive answer to the question “In the last 12
months, have you had wheezing or whistling when you did
not have a cold?”
Shortness of breath: Positive answer to the question “Are
you troubled by shortness of breath when hurrying on level
ground or walking up a slight hill?”
Chest tightness: Positive answer to the question “In the last
12 months, have you woken up with a feeling of tightness in
your chest?”
Blood pressure measurement
Systolic and diastolic blood pressures were measured after
the interview and after the participant had sat quietly for 
at least 10 minutes. Pressures were measured twice with an
interval of at least 3 minutes using an automatic OMRON
705 CP (Tokyo, Japan) with the cuff attached to the naked
left upper arm.
Collection and fractioning of blood samples
Blood samples were taken from all subjects who had con-
sented to the general blood marker analyses and/or the 
genetic analyses. 45 ml of blood was collected for blood
marker analysis into differently coated 9 ml Monovette
tubes (SARSTEDT; Nuembrecht, Germany). EDTA-coated
tubes were used for collection of blood, plasma and buffy
coat, Lithium-Heparin-coated tubes for plasma collection
and non-coated tubes for serum collection. With the excep-
tion of one EDTA-coated tube, the samples were centri-
fuged at room temperature (20 °C, 15 min, 1500 g) using 
a UNIVERSAL 32 R centrifuge (Hettich AG, Baech, Swit-
zerland). Subsequently the fractioned and EDTA-buffered
whole blood samples were aliquoted (300 to 500 ml) into 1ml
TPP Cryotubes (Trasadingen, Switzerland) and transferred
to –80° C immediately. The blood sample collection and frac-
tioning procedure was performed within a maximum of four
hours. If possible, 40 aliquots were prepared per subject,
(corresponding to 3 vials of buffy coat, 3 of EDTA-plasma, 
4 of EDTA-buffered whole blood, 10 of Li-He-plasma, and
20 vials of serum). For DNA extraction, 7 ml of whole blood
was collected in EDTA-coated Monovette tubes, which
were stored without previous centrifugation at –80 °C.
Constitution of the blood plasma, serum and DNA banks
The samples extracted from blood were stored in eight
SANYO freezers (Applewood, ON, Canada) with a storage
volume between 519 (U71V) or 728 litres (U50V) that were
connected to emergency back-up systems (including an
alarm system and/or CO2 backup). After completion of the
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data collection phase in spring 2003, all freezers were trans-
ported to one location (University Hospital, Geneva) for
sample sorting. The blood bank containing about 250 000
blood aliquots was split into two identical banks. For reasons
of security and accessibility the two bio banks are now 
located in two different centres for long-term storage (Uni-
versity Hospitals of Geneva and Zurich). During the trans-
port, inside freezer temperatures were monitored and did
not increase above –60 oC at any time. 
The whole blood samples taken for genetic analysis were
transferred on dry ice to the laboratory performing the
DNA extraction (Departments of Molecular Epidemiology
and of Medical Molecular Genetics, University of Zürich).
The blood samples were processed manually using the
PUREGENETM DNA Purification Kit (GENTRA Systems,
Minneapolis, USA). The observed DNA yields ranged from
7–80 µg of DNA obtained from 1 ml of frozen EDTA-
buffered blood. 
Quality of genomic DNA was evaluated in terms of DNA
degradation visually on 0.8% agarose gel electrophoresis
and in terms of purity by performing standard and allele-
specific PCR amplification. 
Subsequently, DNA working solutions were generated by
diluting the DNA with milli-Q-pure water and concentra-
tion was adjusted to 10 ng/µl. Barcode-labelled 2 ml tubes
with screw-caps (SARSTEDT; Nuembrecht, Germany)
were used to store DNA stock and working solutions. DNA
working solutions were kept at –20 °C for long-term and 
4 °C for short-term storage. In analogy to the blood specimen
bank, the DNA stock solutions were transferred for acces-
sibility and security reasons to two locations (Zurich and
Geneva).
A computer-based data bank (Excel format) was estab-
lished, containing an identification code for each participant,
coordinates identifying the location of each type of biologi-
cal sample (serum, both type of plasma, buffy coat, whole
blood, and DNA), the number of vials present, DNA extrac-
tion remarks, concentration and volume of available DNA
stock solution, DNA quality characteristics and the location
of the diluted DNA working solution.
Weight and height measurements
The participants were asked to remove all heavy clothes
such as shoes, jacket, coat etc. For the height assessment,
telescopic scales, model 222, from SECA (Hamburg, Ger-
many) were used. The scale was permanently fixed unto 
the wall and the participant was required to make contact to
the wall with the backside of his head, the upper back, the
rear, the lower legs as well as with his heels during the 
measurement. An electronic scale (T160-T620-T630) from
TERRAILLON (Bradford, MA, USA) was used for the
weight measurements. Weight was displayed digitally in
kilograms to one decimal point. The scales were calibrated
with standardised weights at regular intervals. The height
scales were checked during quality assessment visits.
Carbon monoxide measurement
In order to validate participants answers to smoking habits
end-expiratory carbon monoxide (CO) was measured with
EC50 Micro-Smokerlyzer, (BEDFONT, Rochester, UK).
Participants were asked to first completely exhale, then to
inhale fully, to hold their breath for at least 20 seconds and
finally exhale completely through the mouthpiece of the
measuring device. CO devices were calibrated approxi-
mately every six months.
Spirometry
The same spirometers based on an open system using a mass
flow anemometer (Sensormedics model 2200, Yorba Linda,
USA), meeting American Thoracic Society (ATS) perfor-
mance criteria, were used in both SAPALDIA 1 and 2. A
quality assessment in 2001 demonstrated that measurement
of lung volumes by the eight spirometers were comparable
to one another (Kuna-Dibbert et al. 2005). The same
spirometry protocol was followed in SAPALDIA 1 and 2
that was identical to the protocol in ECRHS (Künzli et al.
1995). Spirometers were calibrated twice a day using a stan-
dardised three litre syringe. Participants performed ma-
noeuvres in a sitting position wearing nose clips. At least
three and up to maximal eight forced expiratory lung 
function manoeuvres were performed in order to obtain 
a minimum of two acceptable results for for both FEV1 and
FVC and the forced expiratory flows (FEF25, FEF50, FEF25–75
and FEF75) were recorded from each manoeuvre. Flow-
volume curves and codes indicating compliance with Ameri-
can Thoracic Society criteria were displayed on computer
screen as each manoeuvre was performed (American 
Thoracic Society 1995) to assist the technicians in the selec-
tion of acceptable manoeuvres. Spirometry technicians were
also required to report problems during the test that could
affect quality of trials. Expiratory flow measures were taken
from the flow-volume curve with the highest sum of FVC
and FEV1. As in SAPALDIA 1, all spirometry outputs were 
visually screened by respiratory physicians experienced in
lung function testing. There were 370 flow-volume curves
from 237 participants excluded because of abnormalities
that indicated technical problems during the performance of
the manoeuvre (Townsend et al. 2004).
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Methacholine bronchial challenge
Non-specific bronchial responsiveness was assessed by
bronchial challenge with methacholine chloride in partici-
pants able to produce satisfactory spirometry, and who ful-
filled health criteria. Participants were excluded if they had
had a myocardial infarction in the last 12 months, were tak-
ing medication for heart disease, had epilepsy, were preg-
nant, were lactating and/or were receiving treatment with
any beta blockers including eye drops. The protocol follow-
ed in SAPALDIA 2 was identical to that in SAPALDIA 1.
Methacholine (PROVOCHOLINE®, Methapharm Inc.,
ON, Canada) was administered by MEFAR aerosol dosime-
ters (Anandic Medical Systems, Diessenhofen, CH) starting
with inhalation of physiological sodium chloride (NaCl) 
followed by increasing concentrations of methacholine up to
a cumulative dose of 2 mg. The dosimeter was triggered 
automatically at the beginning of the inhalation and the sub-
jects were instructed to hold their breath at full inspiration
for four seconds. Between one and two minutes after the end
of each inhalation two FEV1 manoeuvres were performed
and the manoeuvre with the highest FEV1 recorded. The test
was stopped when either the cumulative dose of 2 mg had
been reached or FEV1 had fallen by 20% or more compared
to the NaCl baseline value or the participant refused to con-
tinue. A bronchodilator (Salbutamol®, 200 mg) was offered
to participants who experienced a drop in FEV1 during the
challenge. Seven new Mefar nebulisers were purchased for
SAPALDIA 2. All nebulisers were calibrated in 2001 by the
manufacturers in Melbourne Australia. Driving pressures
from the Mefar dosimeters were checked periodically at the
centres using a manometer. All challenge tests were assessed
for compliance with the study protocol.
24 hour Holter electrocardiogram (ECG)
Only participants aged 50 and older were eligible for a 
24 hour electrocardiogram (ECG) monitoring with a Holter
recorder (Aria, Del Mar Medical Systems, Irvine Califor-
nia). Exclusion criteria included having a cardiac pace-
maker, having undergone anaesthesia during the previous
eight days or having taken anti-arrythmic drugs class I or III
or digitalis glycosides within the last 30 days.
The Holter monitor was fitted by placing one of three elec-
trodes (Blue Sensor, Medicotest, Stykke, Denmark) 2 cm to
the right of processus xiphoideus, another electrode on the
left linea medioclavicularis on the lowest rib and the third
electrode was located on the left front axillar line on the 
lowest rib. During the ambulatory ECG monitoring period,
participants completed a location and activity diary derived
from a diary previously developed for the EXPOLIS study
(Jantunen et al. 1998). The SAPALDIA ECG diary con-
tained fields for recording information on the participants
whereabouts (indoor, outdoor etc), levels of activity, caf-
feine and alcohol use, consumption of tobacco (active and
passive) and medication for every 15 minute interval during
the monitoring period.
Quality control procedures
Instruction protocols for all methods and parts of the study
were prepared in a written form. Fieldworkers participated
in a three day training workshop, before the beginning of 
the study. Each fieldworker was required to test at least 10
volunteers at the centre under supervision before starting to
examine participants. Three additional workshops for field-
workers were held during the data collection period to 
assure high data quality. In addition, quality control visits to
all eight centres were conducted three times during the ex-
amination phase. At each visit at least one full examination
was observed and possible improvements were discussed
with the fieldworkers. Furthermore, compliance with re-
quired standardised operating procedures was checked and
oral and written feedback provided. Moreover, differences
in the quality between fieldworkers and centres in the con-
duct of spirometry were assessed in detail and reported back
to the fieldworkers. The quality control visits also offered a
platform for feedback from the local teams about the par-
ticipation rates and quality of the recorded data received by 
the central coordinating team. During the data collection 
period, six SAPALDIA bulletins with information and feed-
back were distributed to all centres. The bulletins addressed
issues relating to data collection and quality and provided
additional information about topics that had been raised
during workshops and quality control visits.
Environmental data
In each SAPALDIA region, criteria gases (NO2, SO2, ozone)
and fine particles (PM10, PM2.5) have been monitored at cen-
tral sites. The core of these air pollution measurements have
been conducted within the national (NABEL) and cantonal
monitoring networks, providing long-term routine data for
six of the eight SAPALDIA regions. Measurements initiated
by SAPALDIA closed the gaps in the monitoring network
(Montana and Wald) and regarding parameters not routi-
nely assessed (PM2.5). 
Air quality standards for PM10 were introduced in Switzer-
land in 1996 making measurement of PM10 mandatory. Mea-
surement of PM10 by Harvard impactors was introduced in
the SAPALDIA regions already in 1993. The changes in
PM10 measuring technologies since then have been taken
into account for calculating PM10 time series between 1991
and 2002. Annual means of PM10 before 1997 could be esti-
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mated as fraction of total suspended particulates (TSP)
(Gehrig & Hofer 1999) in Geneva, Lugano, Basel, Payerne
and Davos, while in Wald and Montana Harvard impactor
data was converted to the reference method Digitel HiVol
sampling (Monn & Krütli 1999). PM2.5 has been measured in
all SAPALDIA areas since 1999. Personal, indoor and out-
door NO2 has been measured by SAPALDIA participants in
1992/93 using palmes tubes (Monn et al. 1998) and indoor
and outdoor NO2 again in 2002/03. In addition to air pol-
lutants, meteorological parameters and pollen data have
been collected for each SAPALDIA area. 
In SAPALDIA 1, exposure assignment relied predomi-
nantly on data from a single monitor in each community.
Most participants lived within seven kilometers of the local
monitoring stations and we had demonstrated that parti-
culate matter, one of our primary indicators of ambient air
pollution, is homogeneously distributed within such distan-
ces and not much affected by local traffic (Röösli et al. 2000;
2001). Moreover, we have found ambient PM2.5 from out-
door sources to be correlated with personal exposure to
PM2.5 (Oglesby et al. 2000). As indicator of spatially less 
homogenous traffic-related pollutants, we chose NO2 as 
primary candidate, and conducted complementary neigh-
borhood monitoring in SAPALDIA1. The latter showed 
associations with lung function within areas not observed
with PM10 (Schindler et al. 1998). 
In SAPALDIA 2 the single monitor approach was extended
towards individual exposure estimates. The goal is the assign-
ment of individual long-term air pollution exposure to each
subject, taking into account changes in residential location
during the 11 year follow-up period. Approximately 20% of
SAPALDIA 2 participants moved from their original study
area in SAPALDIA 1. Therefore, estimates of ambient con-
centrations of air pollutants from other areas need to be in-
corporated into exposure estimates. Exposure estimates for
SAPALDIA 2 participants will be derived from NO2, PM10
and PM2.5 maps resulting from emission-based models using
Geographical information system technology (GIS) which
have been validated by monitoring data from fixed sites. The
model for NO2 will be further validated and, if necessary, 
adjusted using outdoor NO2 palm tubes measurements made
by sub-samples of SAPALDIA 1 and SAPALDIA 2 partici-
pants at their homes and GIS-data on traffic-related param-
eters such as distance to street. The resulting models of 
ambient pollutant levels over the follow-up period will then
be linked to the residential locations of SAPALDIA parti-
cipants thereby providing individual exposure estimates.
Results
Participation in examinations
In 1991, 9651 subjects participated in SAPALDIA 1. By
2001, 283 (2.9%) participants had died (194 men, 89
women), 653 (6.8%) had moved abroad or were not trace-
able by March 2003. Therefore, 8715 subjects (93% of the
survivors of the original cohort) could be contacted (Tab. 2).
Of these 8715 subjects, 8047 (92% or 86% of survivors)
completed at least one questionnaire (screening question-
naire, main interview questionnaire or short versions of the
main interview questionnaire). Participants who provided
more information than the screening questionnaire were
classified as responders and as having participated in
SAPALDIA 2 (N=7 680=88% of traceable and 82% of 
living participants in 2001) (Tab. 3a). 
There were 6 528 SAPALDIA 2 participants who performed
spirometry and of these 6 222 provided spirometry data that
met quality criteria. For the methacholine challenge test, 167
participants (2.6%) had to be excluded on the basis of an
FEV1 less than 70% of predicted or less than 1.5L. Other
participants were excluded on the basis of having had a myo-
cardial infarction within the last three months, receiving
medication for heart disease, pregnancy, lactation, treat-
ment with beta blockers (13.3%), no consent for testing 
(7.3%), and other reasons which included doubts about
health status of the participant, unsatisfactory manoeuvres,
technical problems and loss of data (8.2%). Of the 4 655 par-
ticipants who had a bronchial challenge; data from 4211
(90.5%) participants met quality criteria.
We collected blood samples of 6 327 participants who agreed
to blood marker analysis and extracted DNA from blood of
6215 participants who agreed to genetic testing. Of the 
random sample of older participants invited to participate 
in the measurement of ECG; 1 860 provided an ECG for a
continuous period of more than 20 hours. Table 3 a and b
give an overview on participation in examinations and 
the numbers of questionnaires of different types. There 
were 6 207 subjects, representing 66% of the survivors of 
the original cohort, who completed the entire protocol 
(interview, spirometry and blood sample); and valid data is
available for 5973 (62%). 
Description of participants in SAPALDIA 1 and 2 
To test the hypothesis that participation was associated with
health-related behaviours (e.g. smoking) and health status
(e.g. lung function and symptoms), we compared parti-
cipants in both SAPALDIA 1 and 2 to participants who 
only participated in SAPALDIA 1 using data collected at
SAPALDIA 1. Figures 1a and 1 b show the prevalence of
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never and current smokers and selected respiratory symp-
toms in participants in SAPALDIA 1 and SAPALDIA 2. 
An adjusted means procedure was utilised to show the pre-
valence in SAPALDIA 2 adjusted for smoking and symptom
characteristics of all participants in SAPALDIA 1 (STATA
Corporation, Texas 77845, Special Edition release 8.2).
Overall, participants in both SAPALDIA 1 and 2 had slightly
less symptoms in 1991 and were more likely to be non-
smokers than those who did not participate in the follow-up.
As expected there was a small increase in prevalence of
some respiratory symptoms, specially wheeze and classic
phlegm, and a considerable proportion (28%) of smokers
had quit smoking. 
Tables A1 and A2 in the appendix show the distribution of
BMI by age groups and sex. There was a considerable 
increase of weight in this population between assessments
(the mean weight increase was 5.5 kg/person). The mean
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Table 2 SAPALDIA participants in 1991 and traceable and untraceable subjects in 2001–2003, Switzerland
Centre of Subjects in Subjects Subjects Potential Questionnaire Spirometry Broncho- Blood
examination SAPALDIA who died who moved participants  information challenge samples
cross- abroad or in follow-up (= participants)
sectional address is 2001–2003
part991 untraceable
N N N N % N %1) N %2) N %3) N %2)
Basel 1491 59 121 1311 87.9 1192 83.2 861 72.2 591 68.6 806 67.6
Wald 1518 29 36 1453 95.7 1399 94.0 1186 84.8 918 77.4 1178 84.2
Davos 745 16 59 670 89.9 637 87.4 534 83.8 452 84.6 513 80.5
Lugano 1310 35 120 1155 88.2 1140 89.4 908 79.6 589 64.9 870 76.3
Montana 794 25 45 724 91.2 694 90.2 613 88.3 477 77.8 610 87.9
Payerne 1495 54 124 1317 88.1 1168 81.1 882 75.5 611 69.3 856 73.3
Aarau 1299 39 37 1223 94.1 1080 85.7 986 91.3 723 73.3 981 90.8
Geneva 999 27 117 855 85.6 736 75.7 558 75.8 294 52.7 531 72.1
TOTAL 9651 284 659 8708 90.2 8047 85.9 6528 81.1 4655 71.3 6345 78.8
1) Percentage of surviving subjects
2) Percentage of participants
3) Percentage of spirometry
Table 3a Questionnaires submitted to the 2001–2003 follow-up of
SAPALDIA, Switzerland
Nb. of subjects
Screening questionnaire 367
Ultrashort questionnaire 193
Short questionnaire 907
Interview 6573
Spirometry or blood with only a 
screening questionnaire 7
Total 8047
Self-administered questionnaires:
Women’s questionnaire 3153
Menstruation Card 1021
Asthma quality of life 298
SF 36 5703
Epworth sleepiness scale 6092
Occupation list 6045
Medication list 3404
Cardio time activity diary and holter 1807
Residence list 5713
Table 3b Completeness of tests
total Given blood ECG Blood & ECG
number of participants
Interview1) 7673 6345 1813 1763
Interview + spirometry2) 6218 59754) 1693 1649
Interview + spirometry 4113 3998 1054 1035
+ methacholine challenge3)
1) Interview includes subjects who answered either the long, short or ultra-short interview questionnaires and excludes subjects who only answered
the screening questionnaire
2) Spirometry that met good quality criteria
3) Methacholine challenge that met good quality criteria
4) “Complete” examinations meeting quality criteria
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weight gain was highest in younger men and decreased in
both sexes after 55. The Tables in the Appendix also show the
distribution of lung function (measured by forced expiratory
volume in one second and forced vital capacity), the preva-
lence of the selected respiratory symptoms as well as the
prevalence of current smoking and amounts of cigarettes
smoked per day.
Development of air pollutants between SAPALDIA 1 and 2
Ambient concentrations of NO2 and PM10 have decreased in
most SAPALDIA areas since 1991 (Fig. 2a and 2b). In most
areas the strong decrease of the early 1990s was partially lev-
elled out by increasing levels due to meteorological factors
in the years just before SAPALDIA 2, particularly for PM10.
The strongest absolute decline of NO2 was observed in the
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Figure 1a Participation in SAPALDIA in men by smoking status and respiratory symptoms (for definitions, see Methods section), Switzerland, 1991 
and 2002
Figure 1b Participation in SAPALDIA in women by smoking status and respiratory symptoms (for definitions, see Methods section), Switzerland, 1991
and 2002
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Figure 2a 12-year course of NO2 [µg/m3] in the SAPALDIA Regions, Switzerland
Figure 2b 12-year course of PM10 [µg/m3] in the SAPALDIA Regions, Switzerland
Method: Chemilumineszenz
Stations: Geneva: St. Clothilde; Lugano: Lugano NABEL; Aarau: Aarau Luftelektrische Station; Basel: Basel-Binningen NABEL; Payerne: Payerne
NABEL; Wald (Zurich): Wald-Spital; Davos: Davos-Matta; Montana: 1990–1998 Montana-Clinic, since 2002 Montana-Village.
Methods: Digitel HiVol sampling. Data before 1997 converted from TSP (Geneva, Lugano, Basel, Payerne, Davos) and Harvard-data (Wald, Montana)
Stations: Geneva: St. Clothilde; Lugano: Lugano NABEL; Aarau: Aarau Luftelektrische Station; Basel: Basel-Binningen NABEL; Payerne: Payerne
NABEL; Wald (Zurich): Wald-Spital; Davos: Davos-Matta; Montana: 1990–1998 Montana-Clinic, since 2002 Montana-Village.
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two areas with the highest 1991 baseline levels, Geneva and
Lugano, while the alpine area Montana exhibited on a low
level a slight increase. The absolute and relative decline of
PM10 in most areas was less pronounced compared to NO2.
Differences between the areas remain, especially for NO2,
though the air pollution exposure contrast between areas
has been reduced since SAPALDIA 1. 
Discussion
Despite a demanding study protocol, a high participation
rate was achieved in the SAPALDIA follow-up. Comparison
of characteristics at SAPALDIA 1 showed some differences
between SAPALDIA 2 participants and non-participants,
but most differences were small and are unlikely to bias the
main analyses of the study.
The most striking feature was the high proportion of smokers
in 1991 who had quit by 2002. In view of the lower participation
of smokers in 2001 this raises the question of selected 
recruitment; those who gave up might have been more moti-
vated to participate in a health examination. The Swiss natio-
nal Health Survey (Bundesamt für Statistik 2001/2004) shows
an increase in the proportion of former smokers with age (18%
in men aged 35–44 to 42% in the 64–75 age group, with a 
stable proportion in each age group between 1992 and 2002).
The SAPALDIA cohort gained weight in the past 11 years.
The average increase in body mass index (BMI) in young
men was 3.7 kg/m2, on average subjects weighed 5.5 kg 
[SE 0.08] more than in 2002 compared to 1991. The distrib-
ution of BMI in the SAPALDIA population compares
favourably to the MONICA Augsburg population (Gasse et
al. 2002) and the Chianti population (Bartali et al. 2002),
within both sexes and across all age groups, although women
in Innsbruck seem to be slimmer (Ulmer et al. 2001). The
BMI reported by Schilling (Schilling et al. 2001) for Swiss
employees seems comparable to the distribution for women
in our study, but as their results relate to the years 1996–98
one might speculate that the distribution of BMI in their
population might also have been higher in 2002. 
As for the amount of cigarettes smoked, an interesting com-
parison with the Innsbruck Women’s Health Study (Ulmer et
al. 2001) is possible. While the proportion of smokers is con-
siderably higher in Innsbruck (40% in the youngest age group
and 35% in women aged 40–59) the mean number of ciga-
rettes smoked per day is higher in the Swiss female population.
Since these results from SAPALDIA 2 are consistent with
data from other Swiss surveys and prevalence estimates for
symptoms from SAPALDIA 2 did not change much after ad-
justment for differential non-participation we conclude that
the SAPALDIA population sample reflects the distribution of
risk factors for non communicable diseases in an average Swiss
population.
SAPALDIA was designed to investigate the effects of air
pollutants on respiratory health (including lung function, 
development of symptoms and diseases) in a random sample
of the adult population of Switzerland. Given the high par-
ticipation rate in the SAPALDIA follow-up we have suffi-
cient power to test the association of respiratory, allergic and
cardiovascular outcomes with air pollution parameters over
the course of 11 years. In SAPALDIA 2, the urban centres
Basel and Geneva had lower participation rates. We there-
fore expect that the trend towards healthier more educated
participants is amplified in these cities, which might result in
an under-estimation of the effects of ambient air pollution,
since they might live in less polluted places. However since
we are able to look at differences within individuals as well
as by area sampling effects by area become less important.
Throughout the 11 year follow-up period air quality has
been continuously monitored and a steady decline in most
pollutant levels has been observed. The individual long term
exposure assignment (based on personal residential history
and GIS modelling of air pollutant concentrations) will 
increase power to detect the effects of ambient air pollution
at different levels of cumulative exposure (Künzli & Tager
2000). These improvements in individual exposure assign-
ment should counterbalance the relative loss in power due 
to the steady decrease in pollution levels which ultimately
reduces the exposure contrast in the SAPALDIA study.
The DNA collected in the follow-up will enable us to address
emerging questions about the interaction of environmental
and genetic factors in important diseases and might help to
detect especially sensitive subgroups.
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Zusammenfassung
Die Schweizer SAPALDIA-Kohortenstudie (SAPALDIA 2) 1991–
2003: Methoden und Teilnehmendencharakteristika
Fragestellung: Die Schweizer Kohortenstudie Luftverschmut-
zung und Atemwegserkrankungen bei Erwachsenen (SAPAL-
DIA) untersucht die gesundheitlichen Auswirkungen der Lang-
zeitbelastung durch Luftschadstoffe in der Bevölkerung. 
Methoden: 1991 und 2002 wurden ein Interview zur respirato-
rischen Gesundheit und deren Risikofaktoren, eine Spirometrie,
ein bronchialer Reagibilitätstest mit Methacholin, eine end-
expiratorische Kohlenmonoxidmessung und Tests zur allergi-
schen Sensibilisierung durchgeführt. Für SAPALDIA 2 wurde
eine Biobank mit Blut-, Serum-, Plasma- und DNA-Proben ein-
gerichtet. Eine Stichprobe der über 50-jährigen Teilnehmenden
erhielt ein 24-Stunden EKG (Holter). Luftschadstoffkonzentra-
tionen von Stickstoffdioxid (NO2), Schwefeldioxid (SO2), Ozon
(O3) und Schwebstaub (PM10) wurden in allen acht Studien-
gebieten seit 1991 gemessen. Die seit SAPALDIA 1 erfassten
Adressgeschichten und auf GIS-Technologie beruhenden Schad-
stoffverteilungsdaten für NO2 und PM10 werden die Schätzung
der individuellen Langzeitbelastung jedes SAPALDIA-Teilneh-
menden ermöglichen. 
Ergebnisse: Von der ursprünglichen Kohorte von 9 651 Teil-
nehmern in 1991 waren 283 verstorben und Adressen konnten
von 8715 aufgefunden werden. Basisinformationen zum Ge-
sundheitszustand von 8047 Personen (86% aller lebenden 
Personen) wurden erfasst, 6528 (70%) nahmen an der Un-
tersuchung teil und für 5973 (62%) liegen vollständige 
SAPALDIA2-Untersuchungen vor. Nichtteilnehmende waren im
Durchschnitt jünger, weniger gut ausgebildet, eher Raucher und
hatten eher respiratorische Symptome. Die untersuchten Perso-
nen haben in den letzten 11 Jahren durchschnittlich 5,5 kg Kör-
pergewicht zugelegt, 28% der RaucherInnen haben aufgehört
zu rauchen.
Résumé
Etude de cohorte SAPALDIA (Etude Suisse sur la pollution 
atmosphérique et les maladies respiratoires chez l’adulte):
méthodes et caractéristiques des participants
Objectifs: L’étude SAPALDIA a pour objectif de mesurer les 
effets sur la santé d’une exposition à long terme aux polluants
atmosphériques dans la population adulte.
Méthodes: Les participants ont été interrogés en 1991 et en
2002 sur leur état de santé respiratoire et ses facteurs de risque.
Ils ont passé les examens suivants: spirométrie, test de la 
réactivité bronchique et de l’atopie, mesure du CO en fin 
d’expiration. Une banque biologique a été créée. Un ECG
(Holter) a été pratiqué auprès d’un échantillon de participants
âgés de plus de 50 ans. Les concentrations des polluants at-
mosphériques (dioxyde d’azote (NO2), dioxyde de soufre (SO2),
ozone, particules fines (PM10)) ont été mesurées dans huit ré-
gions de Suisse depuis 1991. L’exposition individuelle sur 11 ans
sera déterminée à partir des adresses, de la distribution de NO2
et PM10 et les modèles GIS.
Résultats: Sur les 9 651 participants examinés en 1991, 283 sont
décédés, 87 15 ont été localisés, 8047 ont donné des infor-
mations sur leur état de santé (86 % des personnes en vie), 
6 528 participants (70 %) ont accepté d’effectuer l’examen de
santé et 5 973 (62 %) ont réalisé entièrement le protocole. Les
non participants étaient en moyenne plus jeunes, moins
éduqués, plus fréquemment fumeurs et souffraient plus fré-
quemment de symptômes respiratoires. Les personnes exami-
nées ont pris en moyenne 5,5 kg de poids en 11 ans. 28% des
fumeurs ont cessé de fumer.
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Table A1 Lung function, respiratory symptoms, body mass index and smoking in women of the SAPALDIA cohort, Switzerland
Lung function Female 
Sapaldia 2 FVC Percentiles (P)
Age 
(years) n P10 P25 P50 P75 P90 Mean SD
28–34 277 3.42 3.70 4.03 4.43 4.75 4.06 0.55
35–39 268 3.30 3.61 3.98 4.35 4.83 4.00 0.59
40–44 378 3.26 3.58 3.91 4.32 4.68 3.95 0.56
45–49 440 3.07 3.40 3.77 4.07 4.45 3.77 0.54
50–54 492 2.97 3.26 3.56 3.90 4.24 3.57 0.50
55–59 458 2.81 3.12 3.49 3.82 4.19 3.48 0.56
60–64 399 2.56 2.95 3.32 3.69 4.06 3.31 0.56
65–73 513 2.44 2.67 2.99 3.39 3.69 3.03 0.52
All                         3225 2.76 3.16 3.59 4.00 4.39 3.59 0.64
FEV1 Percentiles (P)
28–34 278 2.75 3.02 3.30 3.59 3.82 3.29 0.45
35–39 267 2.64 2.86 3.17 3.45 3.81 3.18 0.46
40–44 381 2.52 2.80 3.07 3.38 3.60 3.07 0.45
45–49 447 2.33 2.57 2.85 3.15 3.43 2.86 0.45
50–54 493 2.17 2.43 2.68 2.97 3.20 2.69 0.41
55–59 462 2.05 2.30 2.60 2.87 3.09 2.58 0.43
60–64 401 1.88 2.17 2.42 2.71 2.96 2.42 0.44
65–73 505 1.68 1.89 2.17 2.43 2.70 2.17 0.41
All                         3234 2.01 2.35 2.71 3.10 3.44 2.72 0.56
Symptoms Female (n=3978)
Sapaldia 2 Wheeze Chronic phlegm Chronic cough Shortness of breath
Age 
(years) n Mean SD Mean SD Mean SD Mean SD
28–34 352 0.07 0.26 0.05 0.21 0.03 0.18 0.18 0.38
35–39 320 0.07 0.25 0.05 0.22 0.06 0.23 0.18 0.39
40–44 449 0.08 0.28 0.07 0.25 0.06 0.24 0.22 0.41
45–49 541 0.08 0.27 0.05 0.23 0.04 0.21 0.27 0.44
50–54 596 0.09 0.28 0.06 0.24 0.06 0.24 0.31 0.46
55–59 567 0.08 0.27 0.09 0.28 0.07 0.25 0.39 0.49
60–64 495 0.06 0.24 0.08 0.28 0.05 0.22 0.38 0.49
65–73 658 0.08 0.27 0.06 0.24 0.07 0.25 0.46 0.50
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Table A1 (continued)
BMI Female 
Sapaldia 2 Percentiles (P) change in bmi between
Age Sapaldia 1 and 2
(years)
n P10 P25 P50 P75 P90 Mean SD Mean SD
28–34 284 19.22 20.50 22.09 24.91 28.83 23.34 4.33 1.85 2.57
35–39 277 19.24 20.37 22.16 25.21 28.68 23.26 4.23 2.00 2.25
40–44 391 19.43 20.79 23.03 25.96 29.00 23.99 4.88 2.17 2.70
45–49 455 19.81 21.21 23.63 26.75 30.38 24.54 4.65 2.16 2.24
50–54 514 20.32 21.80 24.48 28.01 31.79 25.41 4.92 2.31 2.45
55–59 485 20.24 21.98 24.82 28.50 32.67 25.74 4.88 2.15 2.14
60–64 426 21.38 23.07 25.67 29.10 32.99 26.35 4.54 1.91 2.33
65–73 560 21.50 23.60 26.39 30.11 33.52 27.11 4.90 1.79 2.25
All                         3392 19.95 21.64 24.20 27.83 31.69 25.22 4.89 2.05 2.36
Smoking Female
Sapaldia 2 Cigarettes per day in current smokers
Age
(years) % current Percentiles (P)
n smokers 95% CI n P10 P25 P50 P75 P90 mean SD
28–34 351 25.4 20.9–30.2 89 1 4 10 15 20 10.3 7.7
35–39 319 32.6 27.5–38.0 103 3 7 15 20 20 13.5 9.3
40–44 446 28.5 24.3–32.9 127 2 6 15 20 25 14.6 9.7
45–49 537 31.1 27.2–35.2 167 3 6 15 20 30 14.9 10.3
50–54 591 26.9 23.4–30.7 159 3 10 15 20 30 16.0 10.2
55–59 561 24.1 20.6–27.8 135 2 6 15 20 20 13.7 8.8
60–64 491 17.5 14.2–21.2 85 2 4 10 20 25 12.6 9.6
65–73 652 9.5 7.3–12.0 62 2 5 14.5 20 30 14.9 11.1
All                         3948 23.5 22.2–24.9 927 2 6 15 20 25 14.0 9.7
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Table A2 Lung function, respiratory symptoms, body mass index and smoking in men of the SAPALDIA cohort, Switzerland
Lung function Male 
Sapaldia 2 FVC Percentiles (P)
Age 
(years) n P10 P25 P50 P75 P90 Mean SD
28–34 292 4.67 5.03 5.50 6.11 6.60 5.58 0.77
35–39 279 4.55 4.99 5.43 6.04 6.43 5.51 0.79
40–44 343 4.50 4.85 5.40 5.88 6.33 5.40 0.80
45–49 374 4.26 4.67 5.11 5.63 6.04 5.14 0.71
50–54 416 4.01 4.50 5.00 5.47 5.89 5.01 0.77
55–59 466 3.88 4.28 4.79 5.26 5.72 4.78 0.74
60–64 380 3.74 4.04 4.50 5.04 5.55 4.57 0.74
65–73 430 3.14 3.70 4.11 4.69 5.34 4.19 0.88
All                         2980 3.85 4.38 4.98 5.54 6.08 4.96 0.90
FEV1 Percentiles (P)
28–34 298 3.61 3.92 4.34 4.72 5.21 4.36 0.62
35–39 281 3.54 3.86 4.28 4.67 5.01 4.26 0.64
40–44 341 3.37 3.75 4.15 4.50 4.86 4.13 0.62
45–49 378 3.13 3.50 3.86 4.26 4.61 3.86 0.60
50–54 415 2.92 3.29 3.73 4.11 4.48 3.71 0.65
55–59 466 2.73 3.11 3.52 3.92 4.22 3.47 0.63
60–64 382 2.58 2.95 3.30 3.67 4.09 3.30 0.62
65–73 427 2.08 2.47 2.92 3.34 3.76 2.90 0.67
All                         2988 2.69 3.19 3.72 4.20 4.65 3.69 0.78
Symptoms Male (n=3695)
Sapaldia 2 Wheeze Chronic phlegm Chronic cough Shortness of breath
Age 
(years) n Mean SD Mean SD Mean SD Mean SD
28–34 377 0.13 0.33 0.07 0.26 0.04 0.19 0.09 0.28
35–39 353 0.11 0.31 0.09 0.29 0.07 0.25 0.10 0.29
40–44 414 0.09 0.29 0.09 0.29 0.04 0.20 0.11 0.31
45–49 452 0.08 0.26 0.09 0.28 0.04 0.21 0.14 0.34
50–54 503 0.09 0.28 0.09 0.29 0.06 0.24 0.17 0.38
55–59 576 0.07 0.26 0.08 0.28 0.05 0.21 0.20 0.40
60–64 472 0.08 0.28 0.14 0.34 0.07 0.25 0.26 0.44
65–73 548 0.10 0.31 0.14 0.35 0.06 0.23 0.30 0.46
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Table A2 (continued)
BMI Male 
Sapaldia 2 Percentiles (P) change in bmi between
Age Sapaldia 1 and 2
(years)
n P10 P25 P50 P75 P90 Mean SD Mean SD
28–34 311 21.31 22.82 24.61 26.70 29.09 25.08 3.42 2.79 2.32
35–39 294 21.50 23.16 25.33 27.47 29.48 25.58 3.69 2.17 2.08
40–44 362 21.89 23.74 25.45 27.77 30.68 25.97 3.75 2.07 1.98
45–49 396 21.80 23.66 25.58 28.10 31.28 26.15 3.76 1.77 1.96
50–54 441 22.63 24.09 26.22 28.74 31.80 26.86 4.05 1.80 2.03
55–59 516 23.25 24.97 26.91 29.41 32.70 27.44 3.70 1.82 1.88
60–64 415 22.79 24.73 26.73 29.05 31.90 27.10 3.53 1.31 1.92
65–73 470 23.17 25.01 27.35 29.72 32.31 27.56 3.75 1.29 2.01
All                         3205 22.26 24.03 26.13 28.67 31.59 26.61 3.81 1.82 2.05
Smoking Male
Sapaldia 2 Cigarettes per day in current smokers
Age
(years) % current Percentiles (P)
n smokers 95% CI n P10 P25 P50 P75 P90 mean SD
28–34 372 29.6 25.0–34.4 110 1.5 7 15 20 30 16.6 13.1
35–39 346 34.0 29.1–39.2 118 1 6 20 20 30 16.1 11.6
40–44 350 34.6 30.0–39.4 143 1 7 20 30 35 18.6 13.9
45–49 413 36.0 31.6–40.7 160 <1 6.5 20 27.5 40 19.6 15.5
50–54 447 30.5 26.4–34.7 152 <1 3.5 20 22.5 30 16.2 13.0
55–59 499 27.4 23.7–31.2 157 <1 <1 12 20 30 14.1 13.7
60–64 574 26.3 22.3–30.6 123 <1 <1 12 20 30 13.6 12.8
65–73 467 20.3 17.0–24.0 110 <1 <1 8 20 20 10.4 10.2
All                         3663 29.3 27.9–30.9 1073 <1 4 15 20 30 15.9 13.4
